Skip to content
ES
MARKETS / NASDAQ / KRMD
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

Koru Medical Systems, Inc. KRMD

15 fiscal years on record · USD · FY2025 reported · SEC filings only
$41.1M
▲ 22.2% YoY
$-2.6M
$-470,112
In brief

What this company does

The company's focus is primarily concentrated on its mechanical infusion products, the FREEDOM Infusion Systems, which include the FREEDOM60 Syringe Driver, the FreedomEdge Syringe Driver, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. The company's revenues are derived from three business sources: domestic core (consisting of US and Canada), international core, and pharma services and clinical trials. The Company originally incorporated in March 1980. As of December 31, 2025, the company had 73 full time employees, including 4 international employees.

Written from the business description in KORU Medical Systems, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 12 March 2026. Every sentence was checked against that document before publication.

Growth
USD 41.1M
Revenue, FY2025 · full 15-year series below
Revenue $M Net income $M
FY2025 · Revenue 41.1 · Net income -2.6
20M40M-5M-10M20102012201420162019202120232025
Compound annual growth
+13.8%
+11.2%
+12.9%
+15.2%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +11.2% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−6 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -7.2% · Net -6.4%
10%20%-20%-40%20102012201420162019202120232025
ROE
FY2025 · ROE -15.6%
10%20%-20%-40%20102012201420162019202120232025
Gross margin62.3%
Operating margin-7.2%
Net margin-6.4%
Return on assets-9.5%
EBITDAUSD -2.2M

Each USD of equity lost 16 cents this year.

Cash & shareholders
—
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -0.5
0.8M1.6M-4.0M-8.0M20102012201420162019202120232025
Net buybacks $ Dividends $
FY2019 · Dividends — · Net buybacks -506080.0
-200000-40000020142019
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—

Total assetsUSD 28.2M
EquityUSD 17.0M
CashUSD 8.9M
Current ratio2.44×

Equity funds 60% of total assets.

The 15-year record
15 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
Metric 202520242023202220212020201920182016201520142013201220112010
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.00.00.0−0.00.00.00.00.00.00.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.00.00.0−0.00.00.00.00.00.00.0
Income tax $B0.00.00.0−0.0−0.0−0.00.00.0−0.00.00.00.00.00.00.0
Net income $B−0.0−0.0−0.0−0.0−0.0−0.00.00.0−0.00.00.00.00.00.00.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.00.00.0−0.00.00.00.00.00.00.0
EPS, diluted $−0.06−0.13−0.30−0.19−0.10−0.030.010.02−0.010.020.020.020.020.020.02
Dividend / sh $···············
Payout %···············
ROE %−15.6−32.6−53.2−25.5−12.6−5.15.610.2−7.811.713.114.718.427.128.4
Shares out B0.050.050.050.050.040.040.040.040.040.040.040.040.040.040.03

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 72 reconciliationsAUDITED

Reconciled in 15 of 19 fiscal years. 20 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image